653 related articles for article (PubMed ID: 29068092)
1. High-dose mizoribine combined with calcineurin inhibitor (cyclosporine or tacrolimus), basiliximab and corticosteroids for renal transplantation: A Japanese multicenter study.
Nishioka T; Yoshimura N; Ushigome H; Watarai Y; Nishimura K; Akioka K; Nakamura N; Kawakita M; Yuzawa K; Nakatani T
Int J Urol; 2018 Feb; 25(2):141-145. PubMed ID: 29068092
[TBL] [Abstract][Full Text] [Related]
2. A Prospective Randomized, Comparative Trial of High-Dose Mizoribine Versus Mycophenolate Mofetil in Combination With Tacrolimus and Basiliximab for Living Donor Renal Transplant: A Multicenter Trial.
Ishida H; Takahara S; Amada N; Tomikawa S; Chikaraishi T; Takahashi K; Uchida K; Akiyama T; Tanabe K; Toma H;
Exp Clin Transplant; 2016 Oct; 14(5):518-525. PubMed ID: 27733107
[TBL] [Abstract][Full Text] [Related]
3. The beneficial effect of high-dose mizoribine combined with cyclosporine, basiliximab, and corticosteroids on CMV infection in renal transplant recipients.
Yoshimura N; Ushigome H; Akioka K; Nobori S; Suzuki T; Sakai K; Okamoto M
Clin Exp Nephrol; 2013 Feb; 17(1):127-33. PubMed ID: 23011290
[TBL] [Abstract][Full Text] [Related]
4. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
[TBL] [Abstract][Full Text] [Related]
5. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
[TBL] [Abstract][Full Text] [Related]
6. Excellent results with high-dose mizoribine combined with cyclosporine, corticosteroid, and basiliximab in renal transplant recipients: multicenter study in Japan.
Nishimura K; Uchida K; Yuzawa K; Fukuda Y; Ichikawa Y; Akioka K; Fujisawa M; Sugitani A; Ito S; Nakatani T; Horimi T; Yoshimura N
Transplant Proc; 2012 Jan; 44(1):147-9. PubMed ID: 22310601
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of Tacrolimus without Basiliximab in Well-Matched Living-Donor Renal Transplant Recipients in Korea.
Baek CH; Kim JH; Yu H; Shin E; Cho H; Kim H; Yang WS; Han DJ; Park SK
Exp Clin Transplant; 2016 Aug; 14(4):389-93. PubMed ID: 27228054
[TBL] [Abstract][Full Text] [Related]
8. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
9. Conversion From Cyclosporine to Once-Daily Tacrolimus on 50:1 mg Basis: A Short-Term Pilot Study.
Shimada H; Uchida J; Kosoku A; Iwai T; Kabei K; Nishide S; Naganuma T; Kumada N; Takemoto Y; Nakatani T
Exp Clin Transplant; 2020 Feb; 18(1):1-7. PubMed ID: 31180299
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of the cellular pharmacodynamics of tacrolimus in renal transplant recipients treated with and without basiliximab.
Sugiyama K; Isogai K; Horisawa S; Toyama A; Satoh H; Saito K; Nakagawa Y; Tasaki M; Takahashi K; Hirano T
Cell Transplant; 2012; 21(2-3):565-70. PubMed ID: 22793066
[TBL] [Abstract][Full Text] [Related]
11. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression.
Hernández D; Miquel R; Porrini E; Fernández A; González-Posada JM; Hortal L; Checa MD; Rodríguez A; García JJ; Rufino M; Torres A
Transplantation; 2007 Sep; 84(6):706-14. PubMed ID: 17893603
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
Oh CK; Huh KH; Ha J; Kim YH; Kim YL; Kim YS
Transplantation; 2015 Jan; 99(1):180-6. PubMed ID: 24983307
[TBL] [Abstract][Full Text] [Related]
13. Beneficial Effects of High-Dose Mizoribine on ABO-Incompatible Living-Related Kidney Transplantation: Two-Year Results by a Japanese Multicenter Study.
Harada S; Nakamura T; Ushigome H; Akutsu N; Akioka K; Nakatani T; Yoshimura N
Transplant Proc; 2017 Jun; 49(5):967-970. PubMed ID: 28583569
[TBL] [Abstract][Full Text] [Related]
14. Effects of Antithymocyte Globulin, Basiliximab, and Induction-Free Treatment in Living Donor Kidney Transplant Recipients on Tacrolimus-Based Immunosuppression.
Sonmez O; Ozcan SG; Karaca C; Atli Z; Dincer MT; Trabulus S; Seyahi N
Exp Clin Transplant; 2024 Apr; 22(4):270-276. PubMed ID: 38742317
[TBL] [Abstract][Full Text] [Related]
15. Comparison of tacrolimus and cyclosporine for immunosuppression after renal transplantation: An updated systematic review and meta-analysis.
Azarfar A; Ravanshad Y; Mehrad-Majd H; Esmaeeli M; Aval SB; Emadzadeh M; Salehi M; Moradi A; Golsorkhi M; Khazaei MR
Saudi J Kidney Dis Transpl; 2018; 29(6):1376-1385. PubMed ID: 30588970
[TBL] [Abstract][Full Text] [Related]
16. Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM Study.
Tedesco-Silva H; Pascual J; Viklicky O; Basic-Jukic N; Cassuto E; Kim DY; Cruzado JM; Sommerer C; Adel Bakr M; Garcia VD; Uyen HD; Russ G; Soo Kim M; Kuypers D; Buchler M; Citterio F; Hernandez Gutierrez MP; Bernhardt P; Chadban S;
Transplantation; 2019 Sep; 103(9):1953-1963. PubMed ID: 30801548
[TBL] [Abstract][Full Text] [Related]
17. Excellent results of high-dose mizoribine combined with cyclosporine, basiliximab, and corticosteroids in renal transplant recipients--4-year results.
Yoshimura N; Ushigome H; Nobori S; Suzuki T; Sakai K; Koshino K; Okajima H; Okamoto M
Transplant Proc; 2013 May; 45(4):1472-5. PubMed ID: 23726600
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial.
Nashan B; Schemmer P; Braun F; Dworak M; Wimmer P; Schlitt H
Trials; 2015 Mar; 16():118. PubMed ID: 25873064
[TBL] [Abstract][Full Text] [Related]
19. Immunological risk stratification and tailored minimisation of immunosuppression in renal transplant recipients.
Phanish MK; Hull RP; Andrews PA; Popoola J; Kingdon EJ; MacPhee IAM;
BMC Nephrol; 2020 Mar; 21(1):92. PubMed ID: 32160893
[TBL] [Abstract][Full Text] [Related]
20. Once-daily oral administration of cyclosporine in a lung transplant patient with a history of renal toxicity of calcineurin inhibitors.
Matsuda Y; Chen F; Miyata H; Date H
Interact Cardiovasc Thorac Surg; 2014 Jul; 19(1):171-3. PubMed ID: 24659549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
